RE: Relax21 Apr 2021 01:18
Whilst failure of P3 would result in a drop in sp, SNG is not a 1 trick pony.
COPD is a huge market and was previously said to be worth £2.50 a share. Maybe more like £2 now due to dilution.
We are conducting GOLD standard trials, something that will benefit SNG in the long run. The data we have will, I believe, deliver the best shareholder value, and a likely takeover in 2021. I am really pleased they are taking their time to get the trial bang on. This is the best move imo.
Yes, it is a binary outcome..but thats pharma!!! Who'd have thought we would go ftom 35p to £2.50??? I can see £10 to £12 on a positive p3 trial. £20 if big pharma also want to buy the company...I will be holding until results
All thd best...